Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Rezpegaldesleukin (REZPEG) therapy may lead to continued improvements in hair regrowth and Severity of Alopecia Tool (SALT) scores through 52 weeks among individuals with 

These findings, announced on April 20 by Nektar Therapeutics, represent the updated results of a blinded 16-week extension of the phase 2b REZOLVE-AA study assessing rezpegaldesleukin, an investigational interleukin (IL)-2 pathway agonist designed to selectively expand regulatory T cells, in patients with severe-to-very-severe alopecia areata, or hair loss.

“The new SALT≤20 responders in this set of patients treated out to 52 weeks reflect how the T regulatory cell mechanism of REZPEG can have more clinical benefit over time, a phenomenon the investigators observed in the Phase 2 study in atopic dermatitis as well," Jonathan Silverberg, MD, PhD, MPH, professor of dermatology at The George Washington University School of Medicine and Health Sciences, said in a statement.

92 patients who had been naïve to prior Janus-kinase (JAK) inhibitors or biologic drugs were involved in this global study, with trial investigators randomizing them during a 36-week induction period to be given either 1 of 2 dose regimens of rezpegaldesleukin or placebo. These regimens were administered as twice-monthly subcutaneous injections. Overall, the investigators identified notable baseline disease burden, with mean SALT scores being near 78 in the treatment cohorts and 76.6 in the placebo cohort.

Additionally, there had been a median disease duration of approximately 6 - 7 years. After the study’s induction phase, those who demonstrated some hair regrowth but continued to have significant scalp involvement (SALT >20) were deemed eligible to jin a blinded extension period through Week 52. There were 31 total patients who continued into this phase, including 27 on a rezpegaldesleukin regimen, with a low- (18 µg/kg; n = 14) and high-dose (24 µg/kg; n = 13) cohort. There were 4 remaining on placebo.

In REZOLVE-AA’s extension period, additional clinical responses were observed, with 29% of individuals featured in the low-dose arm and 31% in the high-dose arm attaining new SALT ≤20 responses. This corresponded to ≥80% scalp hair coverage. This was compared with no new responders in the placebo arm of the trial. By the 52-week mark, outcomes across the overall study population continued to favor rezpegaldesleukin therapy.

The proportion of participants with a SALT ≤20 score rose to 25.8% in the low-dose cohort and 27.6% in the high-dose cohort, with only 6.7% in the placebo arm (

 = .049). In a similar finding, the investigative team observed rates of SALT ≤30, representing ≥70% scalp hair coverage, attained by 30.2% and 35.0% of those in the low- and high-dose groups, respectively, versus 8.4% with placebo (

In the team’s additional efficacy endpoints, findings also demonstrated improvements with active treatment. Such results included SALT50 responses observed in 37.7% and 38.8% of individuals in the low- and high-dose arms, respectively. This was compared with only 13.6% noted among those in the placebo arm. SALT30 responses were seen in 45.6% and 47.6% of participants treated with rezpegaldesleukin, versus 24.2% with placebo.

Collectively, these data were described by Nektar as indicators that continued rezpegaldesleukin use may lead to incremental improvements in hair regrowth over time in those living with severe alopecia areata. The company further noted its plans for the REZOLVE-AA results to be submitted for presentation at a medical meeting in 2026.

"Given the prescribing and safety limitations of JAK inhibitors, these new data point to the potential for rezpegaldesleukin to be the first safe and effective biologic in alopecia areata, which may completely transform the management of the disease,” Silverberg said in his statement.

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin. Nektar Therapeutics. April 20, 2026. 

https://www.prnewswire.com/news-releases/52-week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-deepening-of-responses-in-severe-to-very-severe-alopecia-areata-with-rezpegaldesleukin-302746837.html

Chovatiya R. REZOLVE-AD: Rezpegaldesleukin Shows Consistent Efficacy Across Atopic Dermatitis Severity, With Raj Chovatiya, MD, PhD. HCPLive. March 20, 2026. Accessed April 20, 2026. 

https://www.hcplive.com/view/rezolve-ad-rezpegaldesleukin-consistent-efficacy-across-atopic-dermatitis-severity-chovatiya

Articles

Rezpegaldesleukin, an investigational IL-2 pathway agonist intended to selectively expand regulatory T cells, demonstrated deepening clinical activity through 52 weeks in severe-to-very-severe alopecia areata. In a phase 2b global population naïve to prior JAK inhibitors/biologics, baseline SALT scores were ~77 with median disease duration 6–7 years. Among extension-eligible participants with residual SALT >20 after induction, additional new SALT ≤20 responses emerged with both 18 and 24 µg/kg dosing, while placebo showed none.

Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.

Alopecia

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

REZOLVE-AA: 52-Week Data Highlight Positive Alopecia Areata Outcomes with Rezpegaldesleukin

Maria Hordinsky, MD, is an R.W. Goltz Professor of the Department of Dermatology at the University of Minnesota.

Sustained 1-Year Efficacy Seen with Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Cosmo Pharmaceuticals announced positive 12-month phase 3 findings on clascoterone 5% topical solution in men with 

mild-to-moderate androgenetic alopecia (AGA)

, noting the treatment’s sustained efficacy with continued use.

These data highlighting the success of the drug in recent phase 3 clinical trials were discussed by trial investigator Maria Hordinsky, MD, an R.W. Goltz professor of dermatology at the University of Minnesota, who emphasized the significance of the results from both clinical and patient perspectives. The trial program was described as the largest phase 3 program ever done for a topical treatment of androgenetic alopecia in males, with 1465 patients recruited across 51 sites in US and Europe.

“There hasn't been a new FDA…medical treatment, for over 30 years,” Hordinsky noted. “It's been a long time since something has come to this point with with the current medication. We now have the opportunity to really use a topical agent that targets the androgen receptor, one of the key players in androgenetic alopecia.”

In Hordinsky’s view, this positions clascoterone as a potentially important addition to the treatment armamentarium. As a topical androgen receptor inhibitor, the therapy directly targets a key driver of AGA, providing a novel mechanism of action compared to existing choices among patients suffering from such hair loss conditions. She highlighted the clinical relevance of the sustained efficacy observed between Months 6 - 12, describing the continued improvement over time as exciting.

Although she expressed interest in seeing longer-term durability data in real-world settings, Hordinsky underscored these 12-month findings, already, show meaningful persistence of benefit for those with AGA. With regard to the reported 239% relative improvement in target area hair count (TAHC), she stressed while numerical metrics are important, perception among patients also remains central. Hair counts rising can translate into visible, tangible shifts for those with hair loss, aligning clinical outcomes with real-world expectations of improved hair appearance and density.

The trial design, which involved a comparison between subjects on clascoterone and those shifted to vehicle following 6 months, additionally reinforced the value of ongoing use. Those who discontinued active treatment reported a gradual loss of benefit, suggesting consistent use may be necessary to maintain the positive results. Looking ahead, Hordinsky noted clascoterone would likely fit well into a growing and increasingly personalized AGA treatment landscape.

For more information on these data, view the full video interview posted above.

Hordinsky has served on an advisory board for AbbVie (fees) and as an investigator receiving grants or research funding from Arcutis Biotherapeutics, Cassiopea, Concert Pharmaceuticals, Eli Lilly and Company, National Alopecia Areata Foundation, RegenLab, and Sun Pharmaceuticals. She has also received fees for other work with UpToDate, Inc.

Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which Are Statistically Significant. Cosmo Pharmaceuticals. April 15, 2026. Accessed April 20, 2026. 

https://www.cosmohealthconfidence.com/news/98958067-clascoterone-12-month-safety-results-ende

Hordinsky M. Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD. HCPLive. December 18, 2025. Accessed April 20, 2026. 

https://www.hcplive.com/view/phase-3-scalp-study-clascoterone-androgenetic-alopecia-maria-hordinsky-md

Videos

This interview highlights positive 12-month phase 3 results on clascoterone 5% topical solution for mild-to-moderate androgenetic alopecia, or hair loss.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

AstraZeneca said its investigational anti–interleukin-33 monoclonal antibody tozorakimab met the primary end point in the phase 3 MIRANDA trial, reducing the annualized rate of moderate-to-severe exacerbations in former smokers with 

 (COPD) who remained at risk despite inhaled maintenance therapy. The company also reported a meaningful benefit in the overall population including current and former smokers, a key secondary end point in MIRANDA.

“These results add to the growing body of evidence that indicates tozorakimab delivered meaningful clinical benefits for COPD patients who urgently need new treatment options,” Frank Sciurba, MD, FCCP, professor of pulmonary and critical care medicine at the University of Pittsburgh and chief investigator of the LUNA program, said in the company statement.

 If confirmed in full data presentation and regulatory review, the findings could add to a limited biologic treatment landscape in COPD, where exacerbations remain common despite dual or triple inhaled therapy.

MIRANDA is a randomized, double-blind, placebo-controlled phase 3 trial that enrolled 1454 adults with symptomatic COPD and a history of at least 2 moderate or 1 severe exacerbation in the prior 12 months.

 Participants included former and current smokers across blood eosinophil levels and lung function severity stages. Patients received tozorakimab 300 mg every 2 weeks or placebo for 52 weeks on top of inhaled standard of care.

“Tozarakimab is a monoclonal against the IL-33 ligand, and it's involved in a lot of the inflammatory pathways that are affected in COPD. It interestingly affects both Th2 pathways as well as Th1 pathways, and that is of great interest in COPD,” Sciurba said in a 

Only high-level results were disclosed. AstraZeneca did not report absolute exacerbation rates, rate ratios, confidence intervals, or detailed adverse-event frequencies.

 The company said the drug was “generally well tolerated” and that the safety profile was consistent with earlier studies, although a closer look at the data will have to wait for a medical meeting presentation or journal publication.

The MIRANDA announcement follows AstraZeneca’s March report that the replicate phase 3 OBERON and TITANIA trials, which evaluated tozorakimab 300 mg every 4 weeks, also met their primary end points.

 Together, these studies form the core of the LUNA development program, with the ongoing PROSPERO extension focusing on severe exacerbations, including hospitalization and death, over 104 weeks.

Class: anti–IL-33 monoclonal antibody  

Indication: COPD with exacerbation history  

Primary outcome: mod/severe exacerbations  

Status: investigational; filings planned  

COPD remains a major source of morbidity and mortality globally and is the third leading cause of death worldwide excluding COVID-19, according to the World Health Organization.

 Current GOLD guidance emphasizes smoking cessation, vaccination, pulmonary rehabilitation, and inhaled bronchodilator-based therapy, with inhaled corticosteroids used selectively, often guided in part by eosinophil counts and exacerbation history.

 Despite these measures, many patients continue to exacerbate, and repeated events are associated with hospitalization, cardiovascular complications, accelerated disease progression, and death.

Tozorakimab targets IL-33, an upstream alarmin implicated in airway inflammation and epithelial dysfunction.

 Preclinical and translational work suggests the antibody may block signaling from both reduced and oxidized forms of IL-33, including pathways involving ST2 and RAGE/EGFR. In a phase 2a study in COPD, tozorakimab was previously investigated as a strategy to reduce exacerbations, but the precise place of IL-33 inhibition in COPD care remains unsettled pending phase 3 publication and regulatory review.

Clinically, a positive program across former smokers, current smokers, and eosinophil strata would be notable because currently available biologic approaches in COPD have shown variable efficacy and often more selective target populations.

 Still, clinicians will likely want to see whether the effect size differs by smoking status, eosinophil count, concomitant inhaled triple therapy, and baseline exacerbation burden before judging where the drug might fit in practice.

Regulatory submissions are planned, according to the company.

 Key next steps are presentation of complete efficacy and safety data, peer-reviewed publication, and clarification of whether any eventual label would be limited to former smokers, a broader exacerbation-prone COPD population, or specific biomarker-defined groups.

BusinessWire. Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD. April 20, 2026. Accessed April 20, 2026. 

https://www.businesswire.com/news/home/20260420339813/en/Tozorakimab-met-primary-endpoint-in-Phase-III-MIRANDA-trial-in-patients-with-COPD

Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2026 Report. Accessed April 20, 2026. 

https://goldcopd.org/2026-gold-report-and-pocket-guide/

AstraZeneca. Tozorakimab met primary endpoint in both OBERON and TITANIA phase III trials in patients with COPD. Press release. March 27, 2026. Accessed March 27, 2026. 

https://www.businesswire.com/news/home/20260327464200/en/Tozorakimab-met-primary-endpoint-in-both-OBERON-and-TITANIA-Phase-III-trials-in-patients-with-COPD

World Health Organization. The top 10 causes of death. 2024. Accessed April 20, 2026. 

https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

England E, Rees DG, Scott IC, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023;13:9825.  

Singh D, Guller P, Reid F, et al. A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4. Eur Respir J. 2025. doi:10.1183/13993003.02231-2024

AstraZeneca reported that tozorakimab, an anti–IL-33 monoclonal antibody, reduced annualized moderate-to-severe COPD exacerbations in the phase 3 MIRANDA trial among former smokers inadequately controlled on inhaled maintenance therapy, with a meaningful signal in the overall population. MIRANDA randomized 1454 exacerbation-prone patients to tozorakimab 300 mg every 2 weeks vs placebo for 52 weeks on standard of care. Only top-line efficacy and tolerability statements were released; full effect sizes and detailed safety await presentation and publication.

Phase 3 MIRANDA found tozorakimab reduced COPD exacerbations in former smokers despite inhaled maintenance therapy.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Phase 3 MIRANDA Trial Links Tozorakimab to Fewer COPD Exacerbations

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Etovopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care in patients with sickle cell disease, according to topline results from the phase 3 HIBISCUS trial.

Novo Nordisk announced the results on April 20, 2026, with etabopivat meeting both co-primary endpoints, substantially reducing vaso-occlusive crisis events and improving haemoglobin response, 48.7% of people on treatment achieved an increase of >1g/dL after 24 weeks compared to 7.2% with placebo.

“Sickle cell disease severely impacts the lives of millions of people. We are very excited that etavopivat has the potential to be a first and best-in-class therapy and transform the lives of people with sickle cell disease, who currently have limited therapeutic options,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk, in a company statement. “Novo Nordisk remains committed to collaborating with sickle cell disease communities around the world to drive innovation, advance health equity and improve access to treatment and care.”

↑ ATP → improved RBC health and membrane stability

↓ 2,3-DPG → increased hemoglobin–oxygen affinity

Etavopivat is an investigational, once-daily, orally bioavailable, selective Pyruvate kinase red blood cell (RBC) isozyme (PKR) activator. By activating PKR, it enhances glycolysis, leading to increased adenosine triphosphate (ATP) levels (improving RBC health/membrane stability) and decreased 2,3-diphosphoglycerate (2,3-DPG) levels, which increases hemoglobin-oxygen affinity and reduces sickle RBC sickling.

, etavopivat was well-tolerated in people with sickle cell disease and daily use resulted in improvements in vaso-occlusive crises, improvements in fatigue and hemolysis, and increases in hemoglobin levels compared to placebo.

In the randomized, double-blind phase 3 HIBISCUS trial, 400mg etavopivat was evaluated for efficacy and safety compared with placebo. The trial included 385 people ≥ 12 years of age with sickle cell disease.

 385 patients aged ≥12 years with sickle cell disease

 Randomized, double-blind, placebo-controlled

Further, as an exploratory analysis, etavopivat significantly reduced the risk of blood transfusion. Further, as an exploratory analysis, etavopivat significantly reduced the risk of blood transfusion.

The US Food and Drug Administration (FDA) has granted etavopivat Fast Track, Rare Pediatric Disease and Orphan Drug designations. Additionally, etavopivat was granted Orphan Drug designation by the European Commission based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency for the treatment of patients with SCD.

In the second half of 2026, the company plans to submit for the first regulatory approval of etavopivat, while detailed results from HIBISCUS will be presented at a scientific conference in 2026.

Novo Nordisk A/S. Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease. GlobeNewswire News Room. Published April 20, 2026. Accessed April 20, 2026. https://www.globenewswire.com/news-release/2026/04/20/3276770/0/en/novo-nordisk-etavopivat-is-the-first-in-a-new-class-of-drugs-to-meet-both-co-primary-endpoints-in-the-phase-3-hibiscus-trial-substantially-reducing-vaso-occlusive-crisis-events-and.html

Wu G, Dhayakar P. Hibiscus 2 (Trial-in-Progress): A global, Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. 

. 2025;146(Supplement 1):2976-2976. doi:https://doi.org/10.1182/blood-2025-2976

Topline phase 3 data indicate once-daily oral etavopivat, a selective RBC pyruvate kinase (PKR) activator, met both co-primary endpoints in sickle cell disease, delivering a 27% reduction in vaso-occlusive crisis (VOC) events and delaying time to first VOC by roughly four months on background standard of care. Hemoglobin response was notable, with 48.7% achieving >1 g/dL increase at 24 weeks versus 7.2% on placebo. Exploratory analyses suggested reduced transfusion risk. Regulatory momentum includes multiple FDA designations and EU orphan status, with a first filing planned in 2H 2026.

Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Phase 3 HIBISCUS: Etavopivat Cuts VOC Events, Improves Hemoglobin in SCD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Integrating Comparative Evidence to Optimize Psoriasis Treatment Decisions

In the final episode, "Integrating Comparative Evidence to Optimize Psoriasis Treatment Decisions," the panelists explore how the full body of available evidence, including comparative analyses, long term extension studies, real world data, and clinical experience, can be integrated into practical treatment decision making for plaque psoriasis.

The panel opens by outlining the distinct role each type of evidence plays in clinical practice. Comparative studies including MAICs, network meta-analyses, and head to head trials are valued for helping clinicians identify which therapy is most likely to work best for a given patient when all else is equal. Long term extension studies are primarily used to provide patients with reassurance around safety, offering years of accumulated clinical trial safety data with no new emerging signals. Real world data is highlighted as particularly valuable for informing drug persistence and helping clinicians select a therapy that patients are likely to stay on long term, reducing the burden of frequent switching for both the patient and the clinical team. The panel also acknowledges the role of anecdotal clinical experience, noting that when personal observations align with what is seen across clinical trial and real world data, it creates a compelling and well supported basis for treatment recommendations.

The discussion then turns to how community practice dermatologists can apply comparative evidence in their daily practice, with the panel emphasizing the importance of understanding what MAICs are and how to interpret them in the absence of head to head trial data. The panel acknowledges that real world evidence takes time to generate, making other data sources particularly important when evaluating newer agents.

The episode concludes with a summary of the strengths of the IL-23 inhibitor class, including superior efficacy, infrequent dosing, and a strong safety profile, and reinforces that each piece of evidence, from phase three trials to real world analyses, contributes to a complete picture that enables truly holistic and patient centered treatment decisions.

Thank you for watching this Peer Exchange series on psoriasis. Please subscribe to our newsletter for information on upcoming video series.

Video Series

Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

Aliza Narva, JD, discusses how clinical ethics consultation works in practice, from bedside dilemmas to mediation-based approaches and clinician support.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Medical Ethics Unpacked

Medical Ethics Unpacked is a regular multimedia series hosted by Dominic Sisti, PhD, and Steve Levine, MD, spotlighting a spectrum of topics within the field of medical ethics. Throughout the year, hosts will sit down for an in-depth discussion on a specific ethical dilemma within modern healthcare, with some episodes also featuring a special guest. 

Check back throughout the year for discussions on a variety of topics, including data privacy in health apps, euthanasia and medical assistance in dying, reproductive rights and technologies, and more!

Medical Ethics Unpacked: Clinical Ethics Consultation in Practice

In this episode, "Evaluating IL-23 Inhibitors with Long-Term Data and Real-World Evidence," the expert dermatologists explore the distinct but complementary roles of long term extension studies and real world evidence in evaluating the durability and safety of biologic therapies for plaque psoriasis.

Evaluating IL-23 Inhibitors with Long-Term Data and Real-World Evidence

Roy Beck, MD, PhD, is the founder of the Jaeb Center for Health Research.

Beck discusses the recently presented results of INHALE-1, in which technosphere insulin failed to prove noninferiority to RAA but had no pulmonary effects.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

INHALE-1: Afrezza Safe but Not Superior to Rapid-Acting Analogue in Children, With Roy Beck, MD, PhD

Howard Trachtman, MD, is an adjunct clinical professor of pediatrics at the University of Michigan.

Listen to our conversation with Trachtman about sparsentan's recent FDA approval for FSGS.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

In a Q&A from AAD 2026, Elmariah highlights a variety of significant results highlighted in a poser session from the RELIEVE-PN study regarding dupilumab for prurigo nodularis.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

RELIEVE-PN: Prurigo Nodularis Improves Over 6 Months on Dupilumab, With Sarina Elmariah, MD, PhD, MPH

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 04/12

Tozorakimab significantly reduced moderate-to-severe exacerbations in COPD regardless of blood eosinophil count.

Reducing COPD Exacerbations With Tozorakimab, With Frank Sciurba, MD

At AAD, April W. Armstrong, MD, MPH, discussed recent innovations in the atopic dermatitis treatment space, highlighting long-term safety data and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

What's New in Atopic Dermatitis Management, With April Armstrong, MD, MPH

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Experts discuss how metabolic and hormonal factors in women influence MASLD risk, progression, and potential long-term outcomes.

Hepatology

Polycystic Ovary Syndrome

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

MASLD and Women’s Health: The Roles of PCOS and Pregnancy

Beck discusses a recent analysis of the phase 4 trial comparing TI and degludec against standard treatment, highlighting the need for individualized titration.

Latest News

REZOLVE-AA: 52-Week Data Highlight Positive Alopecia Areata Outcomes with Rezpegaldesleukin

Sustained 1-Year Efficacy Seen with Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Phase 3 MIRANDA Trial Links Tozorakimab to Fewer COPD Exacerbations

Phase 3 HIBISCUS: Etavopivat Cuts VOC Events, Improves Hemoglobin in SCD

Integrating Comparative Evidence to Optimize Psoriasis Treatment Decisions